Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab

Annals of Hematology

Volumn 94, Issue 5, 2015, Pages 813-823

  Berinstein, N L ^a,d,f   Bhella, S ^b,d   Pennell, N M ^c   Cheung, M C ^a,d   Imrie, K R ^a,d   Spaner, D E ^a,d   Milliken, V ^a   Zhang, L ^a   Hewitt, K ^a   Boudreau, A ^a   Reis, M D ^c   Chesney, A ^c   Good, D ^c   Ghorab, Z ^c   Hicks, L K ^e   Piliotis, E ^a,d   Buckstein, R ^a,d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Follicular lymphoma; Immunotherapy; Prolonged remission; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; TRANSPLANTATION, AUTOLOGOUS;

EID: 84930352848     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2288-5     Document Type: Article

References (38)

1. Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, Hopkins H, Hutton B, McDiarmid S, Huebsch LB (2007) A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 13(8):956–964. doi:10.1016/j.bbmt.2007.04.009
2. Ganguly S, Divine CL, Deauna-Limayo D, Bodensteiner DC, Cook JD, Lewis JN, Skikne BS (2005) Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Ann Hematol 84(8):526–531. doi:10.1007/s00277-005-1058-9
3. Schouten HC, Kvaloy S, Sydes M, Qian W, Fayers PM (2000) The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 11(Suppl 1):91–94
4. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918–3927. doi:10.1200/JCO.2003.10.023
5. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS (2007) Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25(18):2554–2559. doi:10.1200/JCO.2006.09.8327
6. Peters AC, Duan Q, Russell JA, Duggan P, Owen C, Stewart DA (2011) Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Leuk Lymphoma 52(11):2124–2129. doi:10.3109/10428194.2011.594925
7. Foster M, Gabriel DA, Shea T (2009) Role of hematopoietic stem cell transplant in the management of follicular lymphoma. Oncologist 14(7):726–738. doi:10.1634/theoncologist. 2009-0045
8. Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, Brousse N, Feugier P, Tilly H, Solal-Celigny P, Coiffier B (2008) Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26(21):3614–3620. doi:10.1200/JCO.2007.15.5358
9. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111(8):4004–4013. doi:10.1182/blood-2007-10-116749
10. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramee JF, Arakelyan N, Thyss A, Molucon-Chabrot C, Delepine R, Milpied N, Colombat P, Deconinck E (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113(5):995–1001. doi:10.1182/blood-2008-05-160200
11. Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96(8):1128–1135. doi:10.3324/haematol.2010.030320
12. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M (2005) Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 23(26):6394–6399. doi:10.1200/JCO.2005.07.019
13. Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M (2012) Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 104(1):18–28. doi:10.1093/jnci/djr450
14. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I, To B, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozak T, Dreger P, Uddin R, Ruiz de Elvira C, Goldstone AH (2013) Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 31(13):1624–1630. doi:10.1200/JCO.2012.47.1862
15. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G (1986) High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med 104(2):163–168
16. Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L, Imrie K, Spaner D, Cheung MC, Boudreau A, Reis M, Crump M, Berinstein NL (2009) Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 43(9):701–708. doi:10.1038/bmt.2008.382
17. Pennell N, Woods A, Reis M, Buckstein R, Spaner D, Imrie K, Hewitt K, Boudreau A, Seth A, Berinstein NL (2006) Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction. J Mol Diagn 8(1):40–50. doi:10.2353/jmoldx.2006.050050
18. van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJM (2007) Analysis of minimal residual disease by Ig//TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21(4):604–611
19. Allison PD, SAS Institute (2010) Survival analysis using SAS: a practical guide, 2nd edn. SAS Institute, Cary
20. Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer 89(4):605–611. doi:10.1038/sj.bjc.6601120
21. Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG, Lister TA (2013) Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. Haematologica 98(4):620–625. doi:10.3324/haematol.2012.069583
22. Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M (2008) Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 19(7):1331–1335. doi:10.1093/annonc/mdn044
23. Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23(10):2215–2223. doi:10.1200/JCO.2005.06.146
24. Gribben JG, Hosing C, Maloney DG (2011) Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant 17(1, Supplement):S63–S70. doi:10.1016/j.bbmt.2010.10.011
25. Witzens-Harig M, Dreger P (2010) Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 51(6):967–974. doi:10.3109/10428191003793341
26. Lim SH, Esler WV, Zhang Y, Zhang J, Periman PO, Burris C, Townsend M (2008) B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 49(1):152–153. doi:10.1080/10428190701742506
27. Lim SH, Zhang Y, Wang Z, Esler WV, Beggs D, Pruitt B, Hancock P, Townsend M (2005) Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 35(2):207–208. doi:10.1038/sj.bmt.1704742
28. Shortt J, Spencer A (2006) Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin’s lymphoma. Bone Marrow Transplant 38(6):433–436. doi:10.1038/sj.bmt.1705463
29. Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, Kumano K, Yamaguchi K, Takeda Y, Goto H, Sato N, Koizumi K, Mukai M, Koike T (2007) Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol 137(4):349–354. doi:10.1111/j.1365-2141.2007.06584.x
30. Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB (2012) Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma 53(6):1130–1136. doi:10.3109/10428194.2011.645208
31. Litam JP, Dail DH, Spitzer G, Vellekoop L, Verma DS, Zander AR, Dicke KA (1981) Early pulmonary toxicity after administration of high-dose BCNU. Cancer Treat Rep 65(1–2):39–44
32. Till BG, Madtes DK (2012) BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma 53(6):1019–1020. doi:10.3109/10428194.2011.654341
33. Ghesquieres H (2014) Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks. Leuk Lymphoma:1-2. doi: 10.3109/10428194.2014.974597
34. Salmasi G, Li M, Sivabalasundaram V, Panzarella T, Tsang R, Kukreti V, Crump M, Kuruvilla J (2014) Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma:1-19. doi:10.3109/10428194.2014.963075
35. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122(23):3759–3766. doi:10.1182/blood-2013-06-507319
36. Kornacker M, Stumm J, Pott C, Dietrich S, Sussmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P (2009) Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 20(4):722–728. doi:10.1093/annonc/mdn691
37. Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M (2012) A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol 23(10):2687–2695. doi:10.1093/annonc/mds202
38. Neumann F, Harmsen S, Martin S, Kronenwett R, Kondakci M, Aivado M, Germing U, Haas R, Kobbe G (2006) Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma. Ann Hematol 85(8):530–534. doi:10.1007/s00277-006-0113-5